Alkermes, Inc. (NASDAQ: ALKS) today announced that results from the phase 3 clinical study of VIVITROL® (naltrexone for extended-release injectable suspension) in opioid dependence have been published by The Lancet. The six-month, phase 3 trial met its primary endpoint and showed significantly greater opioid-free weeks among patients treated with VIVITROL, compared to placebo…
-
‹ Home
Contents
-
Categories
-
Tags
addiction aids alcohol alcohol-abuse alcohol-concern alcohol industry association binge drinking brain british cocaine development drugs government Guidance harm-reduction health hiv international journal medical mental mental-health national new-study pmid policy population potential public-health research risk scientific social study substance substance-abuse substance-use the-brain tobacco treatment united united-states university young people
-
Archives
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- April 2008
- March 2008
- July 2007
- January 2007
Blogroll
-
RSS Feeds
-
Meta